Recent advances in liposomes and peptide-based therapeutics for glioblastoma treatment
M.A. Jourdain, Joël Eyer
Abstract
In the context of glioblastoma treatment, the penetration of drugs is drastically limited by the blood-brain-barrier (BBB). Emerging therapies have focused on the field of therapeutic peptides for their excellent BBB targeting properties that promote a deep tumor penetration. Peptide-based strategies are also renowned for their abilities of driving cargo such as liposomal system allowing an active targeting of receptors overexpressed on GBM cells. This review provides a detailed description of the internalization mechanisms of specific GBM homing and penetrating peptides as well as the latest in vitro / in vivo studies of liposomes functionalized with them. The purpose of this review is to summarize a selection of promising pre-clinical results that demonstrate the advantages of this nanosystem, including an increase of tumor cell targeting, triggering drug accumulation and thus a strong antitumor effect. Aware of the early stage of these studies, many challenges need to be overcome to promote peptide-directed liposome at clinical level. In particular, the lack of suitable production, the difficulty to characterize the nanosystem and therapeutic competition leaded by antibodies. • Peptide-based approach as promissing agent for targeting glioblastoma receptors • Peptides attached to liposomes surface enhanced the blood-brain barrier crossing. • Liposomes functionalized with peptides increase drugs therapeutic index. • Peptides personalized therapy and nanosystem optimization remain challenges to overcome.